Utilization of breast preservation treatments in Hispanic patients with breast cancer: An analysis from the National Cancer Data Base (NCDB) from 2000 to 2011.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 76-76
Author(s):  
Alvaro Martinez ◽  
Elisabeth E. Arrojo ◽  
Frank A. Vicini

76 Background: In contrast to mastectomy, radiotherapy (RT) treatments for breast cancer (BC) patients, allows for the benefits of breast preservation therapy and brachytherapy (BT) is a very convenient and short course of RT. BT use in BC has increased since FDA approval in 2002, however, has it been used evenly among races? Methods: Trends of treatment were analyzed for BC patients stages Tis to IV using the NCDB and 2.015.671 cases were found. Specific analysis of treatment differences between Black, White and Hispanic races, and the use of BT was performed. Results: The use of surgery as the only treatment in BC patients has decreased in stages 0 to IV (-7%, -11%, -8%, -6% and -6%; p<0.0001), while the use of RT has increased in stages 0 to III (+5%, +1%, +3%, +8%; p<0.0001). The use of chemotherapy has also increased in stages 0, I, III, IV (+3%, +4%, +7%, +5%; p<0.0001), while decreased in stage II (-3%; p<0.0001). Hispanic patients, received less RT in stages I to III (-4.11%, -5.46%, -4.84%; p<0.05), while White’s in stage I and III (58.11%, 65.98%), and Black’s in stage II (52.19%) received more RT (p<0.05). In addition, Hispanic’s received significantly more mastectomy in stages I, II and IV. BT as a type of RT was used mainly in stages 0 to II. In stages III and IV its use was <0.13%. 50.836 patients stage 0-II received BT. In this group of patients, BT increased from 0.35% in 2000 to 9,76% in 2008 (p<0,0001), and from then, decreased to 8.28% in 2011 (p<0.0001). There are also significant differences between races. In White’s BT increased 11.33% in 2008 which is 1.46 more times than in Black’s and 1.79 more than Hispanic, and then decreased to 9.52% in 2011 which is 1.61 more than in Black’s, and 1.64 more than Hispanic’s. Conclusions: The use of breast preservation RT has increased significantly in stages 0 to III from year 2000 to 2011. BT use increased until year 2008, when it begun to decrease until year 2009, stabilizing in 2010 and 2011 at around 8%. There are significant differences between races in the use of RT in general, and BT in particular, being Hispanic’s the ones which significantly received less breast preservation RT treatment. This finding raises important questions.

Cancer ◽  
1994 ◽  
Vol 73 (7) ◽  
pp. 1994-2000 ◽  
Author(s):  
Robert T. Osteen ◽  
Lucy Hynds Karnell

2016 ◽  
Vol 23 (12) ◽  
pp. 3934-3940 ◽  
Author(s):  
Cristina B. Geltzeiler ◽  
Vassiliki L. Tsikitis ◽  
Jong S. Kim ◽  
Charles R. Thomas ◽  
Daniel O. Herzig ◽  
...  

2017 ◽  
Vol 27 (9) ◽  
pp. 1904-1911 ◽  
Author(s):  
Nataniel H. Lester-Coll ◽  
Melissa R. Young ◽  
Henry S. Park ◽  
Elena S. Ratner ◽  
Babak Litkouhi ◽  
...  

ObjectiveRadiotherapy (RT) is an established adjuvant treatment for stage II endometrioid endometrial carcinoma (EEC). The role of chemotherapy (CT) in stage II EEC is less proven. We used the National Cancer Data Base to identify factors associated with adjuvant CT in stage II EEC and to explore whether receipt of CT was associated with improved overall survival (OS).Methods/MaterialsWomen diagnosed in 2010 to 2013 with International Federation of Obstetrics and Gynecology stage II EEC (grades 1–3) after hysterectomy and bilateral salpingo-oophorectomy were identified in the National Cancer Data Base. Multivariable logistic regression was used to identify covariates associated with receipt of CT. Overall survival among patients receiving RT, CT, or chemoradiotherapy (CRT) after surgery was compared using Kaplan-Meier estimates, the log-rank test, Cox proportional hazards regression, and propensity score matching.ResultsWe identified 6102 stage II EEC patients. There were 358 patients (6%) who received adjuvant CT alone and 525 (9%) who received CRT; the remainder received RT alone (n = 1906; 31%) or no adjuvant treatment (n = 3313; 54%). The presence of lymphovascular invasion (odds ratio, 3.58;P< 0.001) and grade 3 disease (odds ratio, 3.40;P< 0.001) was strongly associated with receipt of CT or CRT. The OS at 3 years for the entire cohort was 89%. On multivariable analysis, CT versus RT was associated with worse OS (hazard ratio [HR], 2.12 [95% confidence interval, 1.46–3.06];P< 0.001), whereas CRT versus RT was not associated with improved OS (HR, 1.07 [95% confidence interval, 0.71–1.62];P= 0.781). After propensity score matching, there remained no difference in OS between RT and CRT (HR, 1.14;P= 0.614).ConclusionsPatients with stage II EEC have an excellent prognosis, and most undergo observation or receive adjuvant RT in the United States. Receipt of CT (alone or with RT) was not associated with an OS advantage compared with RT alone in this observational cohort. Randomized trials will help clarify the role of CT in stage II patients.


Sign in / Sign up

Export Citation Format

Share Document